Key result
Adding olprinone to lipoPGE1 lowers pressure gradient ~56% in an extremely low-birth-weight infant with aortic coarctation.
Why the study?
Does the addition of a PDE3 inhibitor to lipoPGE1 improve the pressure gradient and left ventricular function in an extremely low-birth-weight infant with simple aortic coarctation and left heart failure?
Case Report (n=1)
Does the addition of a PDE3 inhibitor to lipoPGE1 improve the pressure gradient and left ventricular function in an extremely low-birth-weight infant with simple aortic coarctation and left heart failure?
The addition of a PDE3 inhibitor to lipoPGE1 may improve the pressure gradient and left ventricular function in extremely low-birth-weight infants with simple aortic coarctation.
Answers are grounded in this paper and cite their sources.
May support adjunctive PDE3 inhibition in low-birth-weight coarctation; leaves open confirmation in prospective trials.
We herein present a case of simple aortic coarctation (CoA) after ductus arteriosus ligation, in which the combination of a phosphodiesterase-3 (PDE3) inhibitor with liposomal prostaglandin E1 (lipoPGE1) improved the pressure gradient between the upper and lower limbs and enhanced left ventricular function. A female infant was born at 29 weeks 1 day of gestation as the smaller twin in a monochorionic diamniotic pregnancy, with a birth weight of 744 g (-3.0 SD). She was diagnosed with simple CoA at 2 days of age and treated with lipoPGE1. However, because of progressive congestive heart failure, patent ductus arteriosus ligation was performed at 9 days of age. By 21 days of age, the pressure gradient between her upper and lower limbs worsened to 55 mmHg despite continued lipoPGE1 treatment. At that point, the PDE3 inhibitor olprinone was introduced in combination with lipoPGE1. After starting the combination therapy, the pressure gradient decreased to 24 mmHg while the blood pressure in the lower extremities remained similar, and the left ventricular function improved. The PDE3 inhibitor may have contributed to improving the stenosis of the CoA site. Further studies are needed to clarify the efficacy of this treatment.
No takes yet. Share an insight, caveat, or question.
Hawaka et al. (2025) conducted a case report in Simple aortic coarctation and left heart failure (n=1). Phosphodiesterase-3 (PDE3) inhibitor (olprinone) combined with liposomal prostaglandin E1 (lipoPGE1) vs. lipoPGE1 alone (prior to combination) was evaluated on Pressure gradient between upper and lower limbs. In an extremely low-birth-weight infant with simple aortic coarctation, adding the PDE3 inhibitor olprinone to lipoPGE1 reduced the upper-to-lower limb pressure gradient from 55 mmHg to 24 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: